AU2002233082B2 - Long lasting growth hormone releasing factor derivatives - Google Patents

Long lasting growth hormone releasing factor derivatives Download PDF

Info

Publication number
AU2002233082B2
AU2002233082B2 AU2002233082A AU2002233082A AU2002233082B2 AU 2002233082 B2 AU2002233082 B2 AU 2002233082B2 AU 2002233082 A AU2002233082 A AU 2002233082A AU 2002233082 A AU2002233082 A AU 2002233082A AU 2002233082 B2 AU2002233082 B2 AU 2002233082B2
Authority
AU
Australia
Prior art keywords
fmoc
leu
ala
lys
grf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002233082A
Other languages
English (en)
Other versions
AU2002233082A1 (en
Inventor
Corinne Benquet
Nissab Boudjellab
Dominique P. Bridon
Lucie Jette
Roger Leger
Martin Robitaille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Biotechnologies Inc
Original Assignee
ConjuChem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ConjuChem Biotechnologies Inc filed Critical ConjuChem Biotechnologies Inc
Publication of AU2002233082A1 publication Critical patent/AU2002233082A1/en
Priority to AU2005218012A priority Critical patent/AU2005218012A1/en
Application granted granted Critical
Publication of AU2002233082B2 publication Critical patent/AU2002233082B2/en
Assigned to CONJUCHEM BIOTECHNOLOGIES INC. reassignment CONJUCHEM BIOTECHNOLOGIES INC. Request for Assignment Assignors: CONJUCHEM INC.
Assigned to CONJUCHEM BIOTECHNOLOGIES INC. reassignment CONJUCHEM BIOTECHNOLOGIES INC. Request for Assignment Assignors: CONJUCHEM BIOTECHNOLOGIES INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2002233082A 2001-02-02 2002-02-01 Long lasting growth hormone releasing factor derivatives Ceased AU2002233082B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2005218012A AU2005218012A1 (en) 2001-02-02 2005-09-28 Long lasting growth hormone releasing factor derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26642401P 2001-02-02 2001-02-02
US60/266,424 2001-02-02
PCT/CA2002/000123 WO2002062844A2 (en) 2001-02-02 2002-02-01 Long lasting growth hormone releasing factor derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005218012A Division AU2005218012A1 (en) 2001-02-02 2005-09-28 Long lasting growth hormone releasing factor derivatives

Publications (2)

Publication Number Publication Date
AU2002233082A1 AU2002233082A1 (en) 2003-02-13
AU2002233082B2 true AU2002233082B2 (en) 2005-11-10

Family

ID=23014533

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002233082A Ceased AU2002233082B2 (en) 2001-02-02 2002-02-01 Long lasting growth hormone releasing factor derivatives

Country Status (10)

Country Link
US (1) US7268113B2 (enExample)
EP (1) EP1355941A2 (enExample)
JP (3) JP2004520395A (enExample)
CN (2) CN101696240A (enExample)
AU (1) AU2002233082B2 (enExample)
BR (1) BR0206919A (enExample)
CA (1) CA2435563A1 (enExample)
EA (1) EA006484B1 (enExample)
WO (1) WO2002062844A2 (enExample)
ZA (1) ZA200305641B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425729D0 (en) * 1994-09-14 1995-02-22 British Telecomm Otical device
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
DK1180121T3 (da) * 1999-05-17 2004-03-01 Conjuchem Inc Langtidsvirkende insulinotrope peptider
US7112567B2 (en) * 2001-02-16 2006-09-26 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
CN1688696A (zh) * 2002-09-18 2005-10-26 蒙特利尔大学医疗中心 Ghrh类似物
AU2005235634B2 (en) * 2004-04-23 2011-10-20 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
MX2008008076A (es) * 2005-12-22 2008-11-28 Conjuchem Biotechnologies Inc Procesos para la produccion de conjugados preformados de albumina y un agente terapeutico.
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
WO2009009727A2 (en) * 2007-07-12 2009-01-15 Akela Pharma Srl Ghrh analogs and therapeutic uses thereof
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
WO2010121351A1 (en) * 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy
WO2010121352A1 (en) * 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy
WO2011087810A1 (en) * 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
WO2011153491A2 (en) 2010-06-03 2011-12-08 University Of Miami Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
MX355543B (es) 2010-08-13 2018-04-20 Aileron Therapeutics Inc Star Macrociclos peptidomiméticos.
WO2012142706A1 (en) 2011-04-21 2012-10-26 Theratechnologies Inc. Growth hormone releasing factor (grf) analogs and uses thereof
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
US9079974B2 (en) * 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
SG11201404648PA (en) 2012-02-15 2014-09-26 Aileron Therapeutics Inc Peptidomimetic macrocycles
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
WO2014100809A2 (en) 2012-12-21 2014-06-26 University Of Miami Ghrh agonists for the treatment of ischemic disorders
EP2935317B1 (en) 2012-12-21 2019-03-27 University of Miami Ghrh agonists for islet cell transplantation and function and the treatment of diabetes
CN103897053B (zh) * 2012-12-25 2019-01-15 深圳先进技术研究院 化学修饰的胸腺肽α1及其合成方法
CN103665147A (zh) * 2013-11-26 2014-03-26 深圳翰宇药业股份有限公司 一种生长激素释放因子衍生物的合成方法
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
EP3303378B1 (en) 2015-05-28 2021-04-21 Institut National de la Recherche Scientifique Inhibitors of prototypic galectin dimerization and uses thereof
CA3004805A1 (en) 2015-11-18 2017-05-26 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Labyrinthopeptins as anti-viral agents
WO2017223207A1 (en) 2016-06-22 2017-12-28 University Of Rochester Cyclic peptide inhibitors of hedgehog proteins
WO2018085460A2 (en) * 2016-11-02 2018-05-11 Flagship Pioneering, Inc. Compositions and methods for cell delivery
CN108623694B (zh) * 2017-03-24 2021-09-17 北京市肿瘤防治研究所 血管内皮细胞生长因子受体拮抗肽f56的衍生物及应用
US20230022970A1 (en) 2019-12-19 2023-01-26 Transfert Plus, Société En Commandite Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
EP4284828A1 (en) 2021-01-28 2023-12-06 Talem Therapeutics LLC Anti-sars-cov-2 spike glycoprotein antibodies and the therapeutic use thereof
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone
EP4601691A1 (en) 2022-10-14 2025-08-20 Talem Therapeutics LLC Anti-trkb/cd3 antibodies and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4517181A (en) 1982-09-15 1985-05-14 The Salk Institute For Biological Studies Mammalian PGRF
US4529595A (en) 1983-01-13 1985-07-16 The Salk Institute For Biological Studies GRF Analogs
US4563352A (en) 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
US4595676A (en) 1983-04-26 1986-06-17 The Salk Institute For Biological Studies Rat hypothalamic GRF
US4518586A (en) 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US4628043A (en) 1983-04-26 1986-12-09 The Salk Institute For Biological Studies Hypothalamic GRF agonists
US5416073A (en) * 1983-08-10 1995-05-16 The Adminstrators Of The Tulane Educational Fund Growth hormone-releasing peptides and method of treating animals, therewith
US4585756A (en) 1983-10-12 1986-04-29 The Salk Institute For Biological Studies Bovine GRF
US4605643A (en) 1984-03-02 1986-08-12 The Salk Institute For Biological Studies Ovine GRF
US4610976A (en) 1983-08-29 1986-09-09 The Salk Institute For Biological Studies Porcine GRF
US4626523A (en) 1983-09-13 1986-12-02 The Salk Institute For Biological Studies GRF analogs II
US4528190A (en) 1983-10-25 1985-07-09 The Salk Institute For Biological Studies GRF Analogs IV
EP0189673B1 (en) 1984-12-24 1990-09-26 Sumitomo Pharmaceuticals Company, Limited Stable growth hormone releasing factor preparation
CA1271600A (en) 1985-01-07 1990-07-10 David Howard Coy Growth hormone-releasing peptides and method of treating mammals therewith
US4734399A (en) 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4689318A (en) 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4843064A (en) 1987-01-13 1989-06-27 The Salk Institute For Biological Studies GRF analogs V
US4784987A (en) 1987-01-13 1988-11-15 The Salk Institute For Biological Studies GRF analogs VI
JPH03502326A (ja) 1988-01-28 1991-05-30 ポリゲン　ホールディング　コーポレイション 成長ホルモン放出活性を有するポリペプチド化合物類
WO1989007110A1 (en) 1988-01-28 1989-08-10 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US5756458A (en) 1989-06-16 1998-05-26 Pharmacia & Upjohn Company Stabilized potent GRF analogs
DK608589D0 (da) 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
AU666853B2 (en) 1991-04-05 1996-02-29 Genentech Inc. Platelet aggregation inhibitors having high specificity for GP IIbIIIa
AU662731B2 (en) * 1991-04-09 1995-09-14 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
DE4122210C2 (de) 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
CZ281630B6 (cs) 1992-06-12 1996-11-13 Des-Tyr Dynorphin Partnership Analogy des-tyr dynorfinu
EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
WO1996006626A1 (en) 1994-08-26 1996-03-07 Lee Nancy M Analgesic method with dynorphin analogues truncated at the n-terminus
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
NZ318472A (en) 1995-09-21 1999-10-28 Quadrant Healthcare Uk Ltd Composition or conjugate containing a gp60 receptor and a transcytosis enhancer (typically albumin)
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
CN1130222C (zh) * 1996-01-11 2003-12-10 法玛西雅厄普约翰美国公司 水性延长释放配剂
JP2000517308A (ja) 1996-08-30 2000-12-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―２誘導体
ATE218892T1 (de) 1997-11-07 2002-06-15 Conjuchem Inc Affinitätsmarkierer für menschliches serum albumin
IL135835A0 (en) 1997-11-07 2001-05-20 Conjuchem Inc Novel conjugates of opioids and endogenous carriers
JP2002512640A (ja) 1998-03-23 2002-04-23 コンジュケム，インコーポレーテッド 持続性治療薬の局所送達
EP1105409B1 (en) * 1999-05-17 2006-03-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DK1180121T3 (da) 1999-05-17 2004-03-01 Conjuchem Inc Langtidsvirkende insulinotrope peptider
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
HUE045882T2 (hu) 2004-03-23 2020-01-28 Ascendis Pharma Gmbh Polimer prodrug önmagát lehasító linkerrel

Also Published As

Publication number Publication date
ZA200305641B (en) 2004-05-25
US20030073630A1 (en) 2003-04-17
WO2002062844A2 (en) 2002-08-15
JP2004520395A (ja) 2004-07-08
EP1355941A2 (en) 2003-10-29
EA200300856A1 (ru) 2004-08-26
BR0206919A (pt) 2004-07-06
JP2009024017A (ja) 2009-02-05
JP2008106073A (ja) 2008-05-08
CA2435563A1 (en) 2002-08-15
US7268113B2 (en) 2007-09-11
CN1491233A (zh) 2004-04-21
CN101696240A (zh) 2010-04-21
WO2002062844A3 (en) 2003-08-21
EA006484B1 (ru) 2005-12-29

Similar Documents

Publication Publication Date Title
AU2002233082B2 (en) Long lasting growth hormone releasing factor derivatives
AU2002233082A1 (en) Long lasting growth hormone releasing factor derivatives
US7112567B2 (en) Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
AU2002233089A1 (en) Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
US20040266673A1 (en) Long lasting natriuretic peptide derivatives
AU2003246500A1 (en) Long lasting natriuretic peptide derivatives
JP2003527312A (ja) 長期間持続するインシュリン向性ペプチド
KR100629013B1 (ko) Ｉｇｆ-ⅰ 및 -ⅱ를 억제하는 ｇｈ-ｒｈ의 길항 유사체
CN104520314B (zh) 新的具有强效激动效果的gh-rh类似物
ZA200106676B (en) Long lasting insulinotropic peptides.
AU2005218012A1 (en) Long lasting growth hormone releasing factor derivatives
HK1123312A (en) Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
HK1060137A (en) Long lasting growth hormone releasing factor derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CONJUCHEM BIOTECHNOLOGIES INC.

Free format text: FORMER OWNER WAS: CONJUCHEM INC.

PC Assignment registered

Owner name: CONJUCHEM BIOTECHNOLOGIES INC.

Free format text: FORMER OWNER WAS: CONJUCHEM BIOTECHNOLOGIES INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired